These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Ogino I; Watanabe S; Iwahashi N; Kosuge M; Sakamaki K; Kunisaki C; Kimura K Strahlenther Onkol; 2016 Jun; 192(6):359-67. PubMed ID: 26884226 [TBL] [Abstract][Full Text] [Related]
4. Cardiac toxicity in the radiation treatment of esophageal cancer: an emerging concern. Beukema JC; Langendijk JA; Muijs CT Future Cardiol; 2015 Jul; 11(4):367-9. PubMed ID: 26238306 [No Abstract] [Full Text] [Related]
5. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Schytte T; Hansen O; Stolberg-Rohr T; Brink C Acta Oncol; 2010 Oct; 49(7):1058-60. PubMed ID: 20831496 [No Abstract] [Full Text] [Related]
6. Breast Radiation and the Heart: Cardiac Toxicity and Cardiac Avoidance. Harris EER Clin Breast Cancer; 2021 Dec; 21(6):492-496. PubMed ID: 34474986 [TBL] [Abstract][Full Text] [Related]
7. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Wang K; Pearlstein KA; Patchett ND; Deal AM; Mavroidis P; Jensen BC; Lipner MB; Zagar TM; Wang Y; Lee CB; Eblan MJ; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB Radiother Oncol; 2017 Nov; 125(2):293-300. PubMed ID: 29050957 [TBL] [Abstract][Full Text] [Related]
8. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. Jacob S; Pathak A; Franck D; Latorzeff I; Jimenez G; Fondard O; Lapeyre M; Colombier D; Bruguiere E; Lairez O; Fontenel B; Milliat F; Tamarat R; Broggio D; Derreumaux S; Ducassou M; Ferrières J; Laurier D; Benderitter M; Bernier MO Radiat Oncol; 2016 Apr; 11():54. PubMed ID: 27056179 [TBL] [Abstract][Full Text] [Related]
9. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III]. Bustová I Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435 [TBL] [Abstract][Full Text] [Related]
10. Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram. Takeuchi Y; Murakami Y; Kameoka T; Ochi M; Imano N; Takahashi I; Nishibuchi I; Kimura T; Kawahara D; Saito A; Nagata Y J Radiat Res; 2020 Mar; 61(2):298-306. PubMed ID: 32052040 [TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Hirano Y; Onozawa M; Hojo H; Motegi A; Zenda S; Hotta K; Moriya S; Tachibana H; Nakamura N; Kojima T; Akimoto T Radiat Oncol; 2018 Feb; 13(1):23. PubMed ID: 29426342 [TBL] [Abstract][Full Text] [Related]
12. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Niska JR; Thorpe CS; Allen SM; Daniels TB; Rule WG; Schild SE; Vargas CE; Mookadam F Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):931-950. PubMed ID: 30360659 [TBL] [Abstract][Full Text] [Related]
13. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Kole TP; Aghayere O; Kwah J; Yorke ED; Goodman KA Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1580-6. PubMed ID: 22284687 [TBL] [Abstract][Full Text] [Related]
15. Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. Cominos M; Mosleh-Shirazi MA; Tait D; Henrys A; Cornes P Br J Radiol; 2005 Dec; 78(936):1069-74. PubMed ID: 16352580 [TBL] [Abstract][Full Text] [Related]
16. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Gayed I; Gohar S; Liao Z; McAleer M; Bassett R; Yusuf SW Int J Cardiovasc Imaging; 2009 Jun; 25(5):487-95. PubMed ID: 19234869 [TBL] [Abstract][Full Text] [Related]
18. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Morota M; Gomi K; Kozuka T; Chin K; Matsuura M; Oguchi M; Ito H; Yamashita T Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):122-8. PubMed ID: 19327900 [TBL] [Abstract][Full Text] [Related]
20. Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients? Beukema JC; Kawaguchi Y; Sijtsema NM; Zhai TT; Langendijk JA; van Dijk LV; van Luijk P; Teshima T; Muijs CT Radiother Oncol; 2020 Aug; 149():222-227. PubMed ID: 32445862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]